Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 4, keine Gesamtzahl für „Revlimid“
Suchtreffer
Begriffe & Kennungen
Revlimid · 4.8 · During treatment cycle 1, 11/81 (14%) patients with high tumour burden were withdrawn from therapy in the lena
Eintrag öffnenRevlimid · 4.8 · Endocrine Disorders Common Hyperthyroidism
Eintrag öffnenRevlimid · 4.8 · Follicular lymphoma The overall safety profile of lenalidomide in combination with rituximab in patients with
Eintrag öffnenRevlimid · 4.8 · Gastrointestinal Not Known Disorders Pancreatitis, Gastrointestinal perforation (including diverticular, intes
Eintrag öffnenRevlimid · 4.8 · Gastrointestinal disorders Gastrointestinal perforations have been reported during treatment with lenalidomide
Eintrag öffnenRevlimid · 4.8 · Grade 3 or 4 thrombocytopenia was observed in the RVd arm to a greater extent than in the Rd comparator arm (1
Eintrag öffnenRevlimid · 4.8 · Grade 4 neutropenia was observed in the RVd arm to a lesser extent than in the Rd comparator arm (2.7% vs 5.9%
Eintrag öffnenRevlimid · 4.8 · Haemorrhagic disorders Haemorrhagic disorders are listed under several system organ classes: Blood and lymphat
Eintrag öffnenRevlimid · 4.8 · Hepatic disorders The following post-marketing adverse reactions have been reported (frequency unknown): acute
Eintrag öffnenRevlimid · 4.8 · Hepatobiliary Not Known Not Known Disorders Acute hepatic failure^, Hepatitis toxic^, Cytolytic Acute hepatic
Eintrag öffnenRevlimid · 4.8 · High tumour burden was defined as at least one lesion ≥ 5 cm in diameter or 3 lesions ≥ 3 cm.
Eintrag öffnenRevlimid · 4.8 · In a post-hoc analysis of a clinical trial of lenalidomide in myelodysplastic syndromes, the estimated 2-year
Eintrag öffnenRevlimid · 4.8 · In mantle cell lymphoma patients, lenalidomide is associated with a higher incidence of Grade 3 or 4 neutropen
Eintrag öffnenRevlimid · 4.8 · In myelodysplastic syndromes patients, lenalidomide is associated with a higher incidence of Grade 3 or 4 neut
Eintrag öffnenRevlimid · 4.8 · In study MCL-002 there was overall an apparent increase in early (within 20 weeks) deaths. Patients with high
Eintrag öffnenRevlimid · 4.8 · In study NHL-007, TFR was reported in 19/146 (13.0%) of patients in the lenalidomide/rituximab arm versus 1/14
Eintrag öffnenRevlimid · 4.8 · In the CALGB 100104 study, the adverse reactions observed more frequently with lenalidomide maintenance than p
Eintrag öffnenRevlimid · 4.8 · In the IFM 2005-02 study, the adverse reactions observed more frequently with lenalidomide maintenance than pl
Eintrag öffnenRevlimid · 4.8 · In the NHL-007 study the adverse reactions observed more frequently in the lenalidomide/rituximab arm compared
Eintrag öffnenRevlimid · 4.8 · Lenalidomide in combination with rituximab is also associated with a higher incidence of grade 3 or 4 thromboc
Eintrag öffnen